Richard Frank, MD, MHSA, Chief Medical Officer at Vida Health, spoke to Medical News Today about how orforglipron may expand access to GLP-1s: The choice between a pill and an injectable comes down to patient preference and potency. The injectables are clearly more potent but require a weekly injection
We walk with you, offering expert monitoring, adjustments, and support to make sure youre seeing real progress
Nausea, diarrhea, and vomiting were reported by 77.2% of the active treatment group
Agbor, L
For your patients with a valid prescription and commercial insurance, there are savings options available to overcome the affordability barriers of GLP-1 RAs for weight loss with Savings Cards: Wegovy (semaglutide)(obesity) savings card Zepbound (trizepatide) (obesity) savings card Saxenda (liraglutide) (obesity) savings card Ozempic (semaglutide)(diabetes) savings card Trulicity (dulaglutide) (diabetes) savings card Rybelsus (semaglutide) (diabetes) savings card Bydureon Bcise (Exenatide)(diabetes) savings card Patient Assistance Programs: At the time of this writing, Patient Assistance Programs include GLP-1 RAs approved for diabetes (not obesity)
